Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Eingun James Song, MD, is the director of clinical research for Frontier Dermatology. 

Treatment Selection in Psoriasis

In ‘Treatment Selection in Psoriasis,’ our panelists focus on the growing body of long-term data supporting sustained disease control and remission in psoriasis, while also highlighting how these data inform real-world treatment selection. The expert faculty discuss emerging evidence demonstrating that a proportion of patients can achieve and maintain complete skin clearance over several years of continuous therapy. This concept of sustained remission is framed as a more stringent and clinically relevant outcome.

The discussion also explores how long-term durability data translate into everyday clinical treatment decisions. With an expanding number of biologic therapies available, clinicians must navigate the choices within limited patient visit times. The faculty highlights the importance of considering individual patient characteristics, such as comorbidities, body weight, presence of psoriatic arthritis, and treatment history, when selecting the most appropriate therapy.

Additionally, the panelists address the evolving expectations around treatment performance, including speed of response, depth of clearance, and durability. The ability to achieve both fast and sustained results is recognized as a key driver of patient satisfaction and quality of life. They also touch on practical considerations, such as dose adjustments and payer dynamics, which can influence treatment selection in real-world settings. The discussion underscores the shift toward personalized, data-driven decision-making in psoriasis care, where long-term outcomes and patient-specific factors guide the pursuit of sustained remission.

Our next episode, ‘Comparing Biologic Classes and Durability in Psoriasis,’ the faculty compares biologic classes in psoriasis, focusing on differences in speed of response and long-term durability. It highlights how emerging head-to-head data and within-class differences are shaping more individualized treatment decisions.

Videos

New psoriasis data show durable, rapid skin clearance with modern biologics, spotlighting bimekizumab’s four-year remission and patient-tailored selection.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Video Series

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

 has expanded the indication for teplizumab-mzwv (Tzield) to include children as young as 1 year of age with stage 2 

, allowing use to delay progression to clinical (stage 3) disease.

The decision, announced by Sanofi on April 22, 2026, extends prior approval for patients aged 8 years and older and marks the first disease-modifying therapy available for very young children at high risk of developing symptomatic T1D. The expanded indication is supported by safety and pharmacokinetic data from the phase 4 PETITE-T1D study.

"This approval opens an important new chapter in diabetes care for young children with stage 2 type 1 diabetes and their families,” said Kimber Simmons, MD, MS, associate professor of pediatrics at the Barbara Davis Center, in a press release. “This is especially important because these children are often at the highest risk of progressing quickly and without warning. Delaying the onset of stage 3 type 1 diabetes during the years when management is often most difficult because of a child’s small size and dependence on caregivers could have a truly meaningful impact for families."

FDA Expands Tzield Indication to Younger Children With Stage 2 Type 1 Diabetes

Teplizumab is a CD3-directed monoclonal antibody designed to modulate the autoimmune process underlying T1D. It was 

 to delay progression to stage 3 disease in adults and pediatric patients aged 8 years and older with stage 2 T1D.

The updated approval now includes children aged 1 year and older with stage 2 disease, defined by the presence of 2 or more T1D-associated autoantibodies and dysglycemia. This stage precedes symptomatic diabetes but reflects ongoing autoimmune-mediated beta-cell destruction.

The FDA granted the expanded indication under priority review, reflecting the unmet need for interventions that can alter disease progression in early T1D.

The expanded approval is based on data from PETITE-T1D, a phase 4, open-label, single-arm, multicenter study evaluating teplizumab in children younger than 8 years with stage 2 T1D.

The study enrolled 23 participants who received a 14-day course of intravenous teplizumab. The trial was designed primarily to assess safety and pharmacokinetics rather than efficacy outcomes.

Although limited by its small size and nonrandomized design, the study provided supportive evidence that the safety profile of teplizumab in younger children is consistent with that observed in older populations.¹

The approval reinforces a shift toward earlier intervention in T1D, focusing on modifying disease course before the onset of clinical symptoms. At the time of the April 22, 2026 announcement, teplizumab remains the only FDA-approved therapy with this disease-modifying intent in T1D.

Regulatory review is ongoing for an additional indication evaluating whether teplizumab may delay progression in patients with newly diagnosed stage 3 T1D aged 8 years and older.

Teplizumab has also received regulatory approvals in multiple regions outside the US, including the European Union, United Kingdom, and Canada, for delaying progression to stage 3 T1D in patients aged 8 years and older with stage 2 disease.

Sanofi. Press Release: Sanofi’s Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children. Sanofi.com. Published April 22, 2026. Accessed April 22, 2026. 

https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-05-05-00-3278650

 (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D - Nov 17, 2022. Sanofi.us. Published November 17, 2022. Accessed April 22, 2026. 

https://www.news.sanofi.us/2022-11-17-TZIELD-TM-teplizumab-mzwv-approved-by-FDA-as-the-first-and-only-treatment-indicated-to-delay-the-onset-of-Stage-3-type-1-diabetes-T1D-in-adult-and-pediatric-patients-aged-8-years-and-older-with-Stage-2-T1D

Articles

The FDA expanded teplizumab-mzwv (Tzield) to delay progression from stage 2 to stage 3 type 1 diabetes in children aged ≥1 year, extending the prior ≥8-year indication. Stage 2 disease is defined by at least two T1D-associated autoantibodies plus dysglycemia, reflecting active autoimmune beta-cell destruction before symptomatic diabetes. The priority review decision was supported by phase 4 PETITE-T1D safety and pharmacokinetic data from 23 children treated with a 14-day IV course, showing consistency with older populations.

Teplizumab is now approved to treat stage 2 type 1 diabetes in kids 1 year and older.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

FDA News

FDA Expands Teplizumab Approval to Children 1 Year & Older to Delay Type 1 Diabetes Onset

Understanding Biologic Therapies in Psoriasis

In this episode, ‘Understanding Biologic Therapies in Psoriasis,’ the expert dermatologistsexplore the evolving landscape of biologic therapies in psoriasis, focusing on the key differences between therapeutic classes and the clinical importance of having multiple targeted treatment options. The faculty discussed how advances in the understanding of psoriasis pathophysiology, particularly the central IL-23/IL-17 inflammatory pathways have enabled the development of more precise and effective therapies compared with earlier biologics such as TNF-α inhibitors.

The panelists highlighted how first-generation biologics, while effective, were less targeted and associated with broader immune effects, requiring more extensive monitoring and consideration of off-target risks. As newer therapies have emerged, including IL-12, IL-23, and IL-17 inhibitors, clinicians have gained the ability to more selectively modulate the immune system. This has led to improvements in efficacy, safety, and overall treatment outcomes.

The faculty also examined the nuanced differences between targeting upstream versus downstream pathways, including variations in onset of action, durability of response, and potential effects on comorbid conditions such as inflammatory bowel disease. These distinctions underscore why multiple biologic classes are necessary, as no single therapy is optimal for all patients. They emphasized how a clearer understanding of disease biology enhances patient communication. By explaining psoriasis as a dysregulation of a specific immune pathway, clinicians can help patients better understand how targeted therapies work while reassuring them that broader immune function is preserved. Overall, this discussion reinforces the value of personalized treatment selection in modern psoriasis care.

The next episode in this series, ‘Treatment Selection in Psoriasis,’ features the panelists examining long-term data supporting sustained remission in psoriasis and how these findings influence clinical confidence in treatment durability. It also highlights how clinicians incorporate patient characteristics and real-world considerations when selecting biologic therapies to achieve long-term disease control.

Explore how psoriasis biologics differ—TNF vs IL‑23/IL‑17—why classes matter, and what targeted therapy means for safety and results.

ASH Clinical Practice Guidelines in Development and Remaining Evidence Gaps in IDA Management 

An expert reviews the scope and methodology of the ASH clinical practice guidelines on iron deficiency anemia currently in development, identifies the most significant remaining evidence gaps, and summarizes the practical takeaways for clinicians managing IDA today.

The American Society of Hematology is developing its first clinical practice guidelines specifically addressing iron deficiency anemia — a notable undertaking given how common the condition is and how much variation currently exists in diagnostic and management practices. The guidelines will address at least 10 clinical questions prioritized for their potential impact on practice, including diagnostic thresholds across populations such as children, pregnant women, and patients with inflammatory conditions; optimal oral iron dosing and formulation selection; IV iron use in specific populations; and preoperative anemia management. The panel includes more than 20 members — hematologists, pediatric hematologists, patient representatives, implementation science experts, and international members — and is applying GRADE methodology with systematic reviews. The guidelines are targeted for publication in Blood Advances.

The most consequential evidence gaps the ASH guidelines are designed to address reflect longstanding uncertainties that clinicians encounter daily. Optimal oral iron formulation and dosing schedules are not definitively established, though alternate-day dosing has gained traction as a tolerability strategy with comparable absorption. Head-to-head comparisons of IV iron formulations in specific populations — including those with IBD — remain limited, leaving formulation choice largely driven by practical and logistical factors rather than population-specific efficacy data. Management of IDA in pediatric and pregnant populations is currently extrapolated from adult data, and the ASH guidelines specifically plan to address these populations with dedicated evidence synthesis rather than continued extrapolation.

In this final segment of the video discussion on IDA management, Richard Godby, MD, synthesizes the practical bottom line for clinicians managing IDA in the current evidence environment. Ferrous sulfate once daily remains the appropriate starting point for most patients, with escalation to IV iron indicated when oral therapy fails, is not absorbed, or is not tolerated. IV iron formulation should be selected based on practical considerations — primarily the number of infusions required — given that all available products are considered safe and similarly efficacious. Godby closes with an emphasis that cutting across every clinical scenario discussed: iron repletion is necessary but not sufficient, and clinicians must maintain focus on identifying and managing the underlying source of iron deficiency to prevent recurrence and achieve durable benefit for their patients.

Learn when IV iron beats pills and when endoscopy matters in GI-related anemia—from bariatric surgery to IBD, celiac, GAVE, angiectasias.

Recent Oral Therapy Developments in Psoriasis, With April W. Armstrong, MD, MPH

 therapies has expanded in recent years, and new data has emerged in recent dermatology meetings expanding upon these drugs’ use among those with inflammatory diseases.

American Academy of Dermatology (AAD) Annual Meeting

 in Denvrer, April W. Armstrong, MD, MPH, of UCLA, spoke about several key highlights from her session on psoriasis, emphasizing the rapidly expanding role of oral medications for individuals with moderate-to-severe plaque psoriasis.

“In this particular session, I refer to both the FDA-approved advanced oral therapies that we've been using for a while, things such as deucravacitinib, as well as apremilast annd our newly FDA-approved oral therapy, icotrokinra,” Armstrong explained.

Armstrong touched on an array of emerging agents known to be reshaping clinical decision-making in the field, including established oral options such as deucravacitinib and apremilast. She also noted icotrokinra’s recent findings regarding its efficacy, pointing to its comparable efficacy to biologics. She noted that these advancements signal a shift toward oral agents as a “next frontier,” providing patients effective, convenient alternative options with favorable safety profiles.

One key aim of her AAD session was to explore the increasing role of TYK2 inhibition. During her discussion of the session, she highlighted the recent milestone of deucravacitinib’s US Food and Drug Administration (FDA) approval for psoriatic arthritis, in addition to its established role in psoriasis. The data, she noted, underscore its growing utility across disease manifestations.

Armstrong further pointed to next-generation TYK2 inhibitors currently in development, which may offer increased specificity and potency, with early results indicating improved clinical performance. Beyond therapeutics, she noted broader themes discussed during the talk, including the value of early intervention, particularly in psoriatic arthritis, to potentially alter long-term disease trajectories for patients.

Additionally, she discussed the ongoing debate the dermatologist’s role in managing comorbidities such as obesity in collaboration with other specialties. Later, she highlighted encouraging data in pediatric and adolescent populations, noting that many medications with FDA approvals for adults appear to be equally, if not more, effective in younger individuals. Taken together, Armstrong framed the current moment in psoriasis care as one of significant progress, marked by expanding options.

The quotes in this video summary were edited for clarity.

Armstrong served as a consultant for and received honoraria from AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI, Incyte, Janssen, LEO Pharma, Eli Lilly, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun, and UCB and has participated in advisory boards for Boehringer Ingelheim and Parexel.

Armstrong A, et al. S043 Psoriasis. Session presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Johnson and Johnson. FDA approves ICOTYDE (icotrokinra), the first and only targeted oral peptide IL-23 receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis. Press release. Published March 18, 2026. Accessed April 21, 2026. 

https://www.jnj.com/media-center/press-releases

Armstrong’s interview highlights oral therapies in the psoriasis treatment space highlighted in her session at the 2026 AAD meeting.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Hematology

Strategic Alliance Partnership

First-Generation Gene Editing in Sickle Cell Faces Real-World Limits Despite Breakthrough Results

Anick Bérard PhD, a researcher at CHU Sainte-Justine in Montreal, professor at the University of Montreal, and an adjunct professor Université Claude Bernard Lyon 1.

In an interview, Bérard discusses population-based data showing no increased risk of major congenital malformations with first-trimester asthma controller use.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Asthma Controllers Safe in First Trimester, With Anick Bérard, PhD

Aliza Narva, JD, BSN, MSN, director of ethics at the Hospital of the University of Pennsylvania.

In a Q&A with Dominic Sisti, Narva discusses ethics consult workflows, common conflicts, and lessons from complex ICU cases.



Clinical Ethics Consultation in Practice, With Aliza Narva, JD, MSN

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Ravulizumab reduced proteinuria by week 10 and met the primary endpoint in the phase 3 I CAN trial in IgA nephropathy.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Breaking News

Ravulizumab Reduces Proteinuria as Early as Week 10 in Phase 3 I CAN Trial for IgAN

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

There is an antifungal-resistant dermatophyte spreading globally, and experts are urging clinicians to become more aware.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

When First-Line Fails: The Rising Threat of Treatment-Resistant Dermatoses

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

If approved, the novel corticosteroid therapy would be the first and only FDA-approved hydrocortisone acetate suppository.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

FDA Accepts NDA For Next-Generation Hydrocortisone Acetate in Ulcerative Colitis of the Rectum

The FDA accepted Genentech's sBLA for obinutuzumab in SLE based on positive phase 3 ALLEGORY trial results, with a decision expected by December 2026.

FDA Accepts sBLA for Obinutuzumab (Gazyva) in Systemic Lupus Erythematosus

Martina J. Porter, MD, is a dermatologist at Beth Israel Deaconess Medical Center.

54-week STOP-HS data show clinically meaningful improvements in pain, fatigue, and quality of life in one-third to two-thirds of patients.


Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Shifting Treatment Goals and Povorcitinib's Benefit in HS, With Martina Porter, MD

Following an April 18 executive order, Gus Alva, MD, discusses psychedelic mechanisms, evidence, and clinical considerations for psychiatry.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

PTSD

White House Order Accelerates Psychedelic Research for Mental Illness, With Gus Alva, MD

Phillip Levy is an Assistant Professor of Emergency Medicine and Assistant Professor of Physiology at Wayne State University and the Assistant Vice President for Research at Wayne State University Department of Emergency Medicine.

Latest News

Treatment Selection in Psoriasis

FDA Expands Teplizumab Approval to Children 1 Year & Older to Delay Type 1 Diabetes Onset

Understanding Biologic Therapies in Psoriasis

ASH Clinical Practice Guidelines in Development and Remaining Evidence Gaps in IDA Management

Recent Oral Therapy Developments in Psoriasis, With April W. Armstrong, MD, MPH